全反式维甲酸联合砷剂时代急性早幼粒细胞白血病治疗进展OA
Advances in the treatment of acute promyelocytic leukemia in the era of ATRA plus Arsenic-based therapy
全反式维甲酸(ATRA)联合砷剂显著改善了急性早幼粒细胞白血病(APL)的治疗结局,推动APL管理向治疗简化、毒性降低和精准化方向发展.文章聚焦ATRA联合砷剂时代APL治疗的重要进展,重点阐述初治策略优化、复发难治治疗进展以及变异型APL和APL样白血病的分子认识与治疗应对,以期为临床实践与未来研究提供参考.
The combination of all-trans retinoic acid(ATRA)and arsenic-based therapy has markedly improved outcomes in acute promyelocytic leukemia(APL),driving a shift in APL management toward treatment simplification,reduced toxicity,and greater precision.This review focuses on the major therapeutic advances in APL in the era of ATRA plus arsenic-based therapy,with particular emphasis on optimization of front-line strategies,progress in the management of relapsed/refractory disease,and evolving molecular insights and therapeutic approaches in variant APL and APL-like leukemia.It also aims to provide a useful reference for clinical practice and future research.
陈丽
上海交通大学医学院附属瑞金医院血液科 上海血液学研究所 组学与疾病全国重点实验室 国家转化医学研究中心,上海 200025
医药卫生
急性早幼粒细胞白血病全反式维甲酸三氧化二砷早期死亡复发难治变异型急性早幼粒细胞白血病靶向治疗
acute promyelocytic leukemiaall-trans retinoic acidarsenic trioxideearly deathrelapsed/refractory diseasevariant acute promyelocytic leukemiatargeted therapy
《中国实用内科杂志》 2026 (7)
537-543,7
上海市血液病学临床专科能力提升项目(SHDC22024314)
评论